🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07217977
Enrolling by invitation Observational

An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD

NCT07217977 · tracked via the Priya Life Science USA tracker
Sponsor
Qbtech AB
Phase
Observational
Started
2025-01-15
Last updated
2026-05-06

Condition(s) studied

Attention Deficit Disorder With Hyperactivity (ADHD)Attention Deficit Disorder (ADD)

Investigational drug(s) / intervention(s)

observational study

observational study: observational study

Study summary

The current study will investigate if QbMobile can be used to improve the accuracy and objective identification of reduced ADHD symptoms in tests scores once treatment has been initiated.

Eligibility

Sex
ALL
Min age
6 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile; * Aged \> 6 years and \< 60 years old; * Referred for an ADHD assessment or has a diagnosis of ADHD but not currently receiving any type of stimulant or nonstimulant medication treatment; * Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation) per sites standard clinical care evaluation; * Qbtech Rating Scale total score of \>24 at Visit 1; * Have adequate sensory and physical ability to complete QbMobile; * Possess or has access to an iPhone model that supports QbMobile. Exclusion Criteria: * Intellectual disability designated by IQ\<75); * Has used psychostimulant medication within 7 days prior to Visit 1; * A concurrent medical diagnosis that could significantly affect test performance (brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g., vascular dementia, Alzheimer disease, etc); * Other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain); * Substance use (e.g., alcohol, drugs) that may affect performance on the day of the test.

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Focus-MD Mobile Alabama
Prodigy Psychiatric Group San Jose California
Bokhari Medical Consortium Largo Florida
CCM Clinical Research Group Miami Florida
Nona Pediatric Center Orlando Florida
Godwin Psychiatry Goldsboro North Carolina
MindWell Urgent Care Dallas Texas

More Qbtech AB trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07217977 on ClinicalTrials.gov ↗ ← All trials in the USA